FXYD2
protein-codingFXYD domain containing ion transport regulator 2
Gene summary
This gene encodes a member of the FXYD family of transmembrane proteins. This particular protein encodes the sodium/potassium-transporting ATPase subunit gamma. Mutations in this gene have been associated with Renal Hypomagnesemia-2. Alternatively spliced transcript variants have been described. Read-through transcripts have been observed between this locus and the upstream FXYD domain-containing ion transport regulator 6 (FXYD6, GeneID 53826) locus.[provided by RefSeq, Feb 2011]
- ATP1G1
- HOMG2
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~27.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AD
Disease ID:MONDO:0007937
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0007937
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0007937
Submitter: ClinGen
FXYD2 was first reported in relation to autosomal dominant renal hypomagnesemia 2 in 2000 (Meij et al. 2000, PMID: 11062458). The gene is associated with low magnesium levels due to a loss of kidney magnesium, as well as hypokalemia, hypocalciuria, and renal failure. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found no relevant differences in molecular mechanism, inheritance pattern or phenotypic variability (there is only one disease assertion for this gene). Therefore, no pre-curation was needed. One variant (the missense variant Gly41Arg) has been reported in 18 probands from one family in 2 publications (PMIDs: 25765846, 11062458) included in this curation. The mechanism of pathogenicity is reported to be loss of function. This gene-disease association is also supported by experimental evidence (biochemical functional evidence, expression level data, functional alteration evidence, and a mouse model; PMIDs: 18787637, 18448590, 18448590, 15755730). In summary, FXYD2 is moderately associated with autosomal dominant renal hypomagnesemia 2. The disease is only associated with one variant in the gene, but there is case-level data (including lots of segregation) and various experimental evidence to support the relationship. Thus, a moderate classification, which was reached based on the point system (7.0 points were reached), felt appropriate. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This gene-disease pair was originally evaluated by the Tubulopathy GCEP on 6/29/2023 (SOP Version 9). It was reevaluated on 12/3/2025 (SOP Version 11). As a result of this reevaluation, the classification did not change. There was no new scorable evidence, despite a new case (PMID: 40428357) that was evaluated but not counted due to lack of phenotypic specificity.
Inheritance Pattern: AD
Disease ID:MONDO:0007937
Submitter: Orphanet
Clinical Genomic Database (CGD)
Manifestation: Renal
Intervention: Renal
Rationale: Surveillance for and treatment of electrolyte abnormalities can be beneficial (eg, to avoid sequelae such as pseudogout, as has been described in affected individuals)
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to FXYD2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001680.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 2 | 12 | 2 | 16 | ||
| missense | 1 | 18 | 5 | 24 | ||
| nonsense | 0 | |||||
| start loss | 0 | |||||
| frameshift | 1 | 1 | ||||
| splice donor/acceptor (+/-2bp) | 1 | 1 | 2 | |||
| Total | 1 | 0 | 22 | 18 | 2 | 43 |
Highest pathogenic variant AF is 7.1018286e-7
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001671.2 | 5 | MANE Select | |
| Ensembl | ENSP00000292079.2 | 5 | MANE Select | |
| RefSeq | NP_067614.1 | 5 | Standard | |
| Ensembl | ENSP00000260287.2 | 5 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Cardiac muscle contraction - Homo sapiens (human)
- Thyroid hormone synthesis - Homo sapiens (human)
- Protein digestion and absorption - Homo sapiens (human)
- Bile secretion - Homo sapiens (human)
- Carbohydrate digestion and absorption - Homo sapiens (human)
Biological Process
- establishment or maintenance of transmembrane electrochemical gradient
- sodium ion export across plasma membrane
- ATP hydrolysis coupled transmembrane transport
- potassium ion import across plasma membrane
- regulation of sodium ion transmembrane transporter activity
Molecular Function
- transporter activity
- sodium:potassium-exchanging ATPase activity
- sodium channel regulator activity
- ion channel regulator activity
Cellular Component
- plasma membrane
- sodium:potassium-exchanging ATPase complex
- extracellular exosome
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000292079
- Coding exons
- 5
- Length
- 27855
- Individuals with no LoFs
- 125469
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 2
- Defined
- 125471
- p
- 0.00000797
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | -0.156 | 49 | 46.0 | 1.06 | 0.00000312 | 426 |
| Missense (PolyPhen) | 20 | 17.963 | 1.1134 | 185 | ||
| Synonymous | -0.977 | 23 | 17.8 | 1.29 | 0.00000130 | 114 |
| Loss of Function | 1.30 | 2 | 5.21 | 0.384 | 2.21e-7 | 67 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0 | 0.0 | absent |
| South Asian | 0.000065 | 0.000065 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: May be involved in forming the receptor site for cardiac glycoside binding or may modulate the transport function of the sodium ATPase.;
Intolerance Scores
- LoFtool
- 0.281
- RVIS EVS
- 0.19
- RVIS percentile EVS
- 66.82
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.000434
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |